Zaltrap

Active Ingredient(s): Ziv aflibercept
FDA Approved: * August 3, 2012
Pharm Company: * SANOFI AVENTIS US
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zaltrap Overview

Aflibercept, sold under the brandname Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and Europe.[2][3] It is an inhibitor of vascular endothelial growth factor (VEGF).[4][5] Contents 1 Medical use 2 Contraindications 3 Adverse effects 4 Interactions 5 Mechanism of action 6 Composition 7...

Read more Zaltrap Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Aflibercept

Recent Zaltrap Forums:

Possible Dosages for this and Related Drugs:

NDC Database Records for Zaltrap: (2 results)

Sorted by National Drug Code

• 0024-5840 Zaltrap 100 mg/4ml Intravenous Solution, Concentrate by Sanofi-aventis U.S. LLC
• 0024-5841 Zaltrap 200 mg/8ml Intravenous Solution, Concentrate by Sanofi-aventis U.S. LLC

Other drugs which contain Ziv aflibercept or a similar ingredient: (1 result)

• ZIV AFLIBERCEPT

Related Zaltrap Topics: